EW Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 25.34% compared to Edwards Lifesciences's net margin of 14.45%. Edwards Lifesciences's return on equity of 46.91% beat Boston Scientific's return on equity of 9.57%.

Edwards Lifesciences has a consensus price target of $80.87, signalling upside risk potential of 7.61%. On the other hand Boston Scientific has an analysts' consensus of $117.02 which suggests that it could grow by 17.33%. Given that Boston Scientific has higher upside potential than Edwards Lifesciences, analysts believe Boston Scientific is more attractive than Edwards Lifesciences.

Edwards Lifesciences has a beta of 1.118, which suggesting that the stock is 11.762% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.681, suggesting its less volatile than the S&P 500 by 31.908%.

Edwards Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edwards Lifesciences pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Edwards Lifesciences quarterly revenues are $1.4B, which are smaller than Boston Scientific quarterly revenues of $4.7B. Edwards Lifesciences's net income of $358M is lower than Boston Scientific's net income of $674M. Notably, Edwards Lifesciences's price-to-earnings ratio is 10.74x while Boston Scientific's PE ratio is 72.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences is 8.08x versus 8.46x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 25.34% compared to Edwards Lifesciences's net margin of 30.99%. Edwards Lifesciences's return on equity of 46.91% beat Intuitive Surgical's return on equity of 15.82%.

Edwards Lifesciences has a consensus price target of $80.87, signalling upside risk potential of 7.61%. On the other hand Intuitive Surgical has an analysts' consensus of $575.49 which suggests that it could grow by 12.36%. Given that Intuitive Surgical has higher upside potential than Edwards Lifesciences, analysts believe Intuitive Surgical is more attractive than Edwards Lifesciences.

Edwards Lifesciences has a beta of 1.118, which suggesting that the stock is 11.762% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.669, suggesting its more volatile than the S&P 500 by 66.875%.

Edwards Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edwards Lifesciences pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

Edwards Lifesciences quarterly revenues are $1.4B, which are smaller than Intuitive Surgical quarterly revenues of $2.3B. Edwards Lifesciences's net income of $358M is lower than Intuitive Surgical's net income of $698.4M. Notably, Edwards Lifesciences's price-to-earnings ratio is 10.74x while Intuitive Surgical's PE ratio is 75.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences is 8.08x versus 21.34x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Steris PLC has a net margin of 25.34% compared to Edwards Lifesciences's net margin of 9.84%. Edwards Lifesciences's return on equity of 46.91% beat Steris PLC's return on equity of 9.5%.

Edwards Lifesciences has a consensus price target of $80.87, signalling upside risk potential of 7.61%. On the other hand Steris PLC has an analysts' consensus of $263.10 which suggests that it could grow by 9.02%. Given that Steris PLC has higher upside potential than Edwards Lifesciences, analysts believe Steris PLC is more attractive than Edwards Lifesciences.

Edwards Lifesciences has a beta of 1.118, which suggesting that the stock is 11.762% more volatile than S&P 500. In comparison Steris PLC has a beta of 0.937, suggesting its less volatile than the S&P 500 by 6.329%.

Edwards Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Steris PLC offers a yield of 0.95% to investors and pays a quarterly dividend of $0.57 per share. Edwards Lifesciences pays -- of its earnings as a dividend. Steris PLC pays out 35.77% of its earnings as a dividend. Steris PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Edwards Lifesciences quarterly revenues are $1.4B, which are smaller than Steris PLC quarterly revenues of $1.5B. Edwards Lifesciences's net income of $358M is higher than Steris PLC's net income of $145.7M. Notably, Edwards Lifesciences's price-to-earnings ratio is 10.74x while Steris PLC's PE ratio is 38.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences is 8.08x versus 4.38x for Steris PLC. Usually stocks with elevated PS ratios are considered overvalued.

Zimmer Biomet Holdings has a net margin of 25.34% compared to Edwards Lifesciences's net margin of 9.53%. Edwards Lifesciences's return on equity of 46.91% beat Zimmer Biomet Holdings's return on equity of 7.29%.

Edwards Lifesciences has a consensus price target of $80.87, signalling upside risk potential of 7.61%. On the other hand Zimmer Biomet Holdings has an analysts' consensus of $107.50 which suggests that it could grow by 17.77%. Given that Zimmer Biomet Holdings has higher upside potential than Edwards Lifesciences, analysts believe Zimmer Biomet Holdings is more attractive than Edwards Lifesciences.

Edwards Lifesciences has a beta of 1.118, which suggesting that the stock is 11.762% more volatile than S&P 500. In comparison Zimmer Biomet Holdings has a beta of 0.717, suggesting its less volatile than the S&P 500 by 28.281%.

Edwards Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zimmer Biomet Holdings offers a yield of 1.05% to investors and pays a quarterly dividend of $0.24 per share. Edwards Lifesciences pays -- of its earnings as a dividend. Zimmer Biomet Holdings pays out 21.69% of its earnings as a dividend. Zimmer Biomet Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Edwards Lifesciences quarterly revenues are $1.4B, which are smaller than Zimmer Biomet Holdings quarterly revenues of $1.9B. Edwards Lifesciences's net income of $358M is higher than Zimmer Biomet Holdings's net income of $182M. Notably, Edwards Lifesciences's price-to-earnings ratio is 10.74x while Zimmer Biomet Holdings's PE ratio is 20.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences is 8.08x versus 2.40x for Zimmer Biomet Holdings. Usually stocks with elevated PS ratios are considered overvalued.